Urothelial malignancies, including carcinomas of the bladder, ureters, and renal pelvis
comprised∼ 8% of new cancer cases in the USA in 2016. In the metastatic setting, 15% of …

Background To date, there have been no reports characterizing the genome-wide somatic
DNA chromosomal copy-number alteration landscape in metastatic urothelial carcinoma …

Neuroendocrine bladder cancer is a relatively rare but often lethal malignancy, with cell of
origin, oncogenomic architecture and standard treatment poorly defined. Here we performed …

Next-generation sequencing (NGS) refers to technologies that decipher nucleic acid
information at the single-molecule level. This high resolution contrasts with conventional …

Background In patients with rare histologies of bladder cancer, including adenocarcinoma of
the bladder (ACB) and squamous-cell carcinoma (SCC), there are limited standard therapy …

The molecular characteristics of metastatic upper tract urothelial carcinoma (UTUC) are not
well understood, and there is a lack of knowledge regarding the genomic and transcriptomic …

Cancers arising from the urothelium, the specialized epithelial lining of the urinary system,
include urothelial carcinoma of the bladder (UCB) and upper tract urothelial carcinoma …

Purpose: Targeted agents and immunotherapies promise to transform the treatment of
metastatic bladder cancer, but therapy selection will depend on practical tumor molecular …

Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic
chemotherapy have plateaued. Recent technological advances allows for a comprehensive …

Background Upper urinary tract urothelial cancer (UTUC) may have unique etiologic and
genomic factors compared to bladder cancer. Objective To characterize the genomic …